2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15571A
    VCH-286 891824-47-8 98%
    VCH-286 is a CCR5 inhibitor that exhibits potent in vitro anti-HIV-1 activity when used alone.
    VCH-286
  • HY-155720
    Mtb-IN-4 2306039-13-2 98%
    Mtb-IN-4 (compound 17h) is a nontoxic isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity (IC50=0.70 μM). Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant.
    Mtb-IN-4
  • HY-155722
    Mtb-IN-5 2954888-39-0 98%
    Mtb-IN-5 (compound (-)17j) is an isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity. Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant.
    Mtb-IN-5
  • HY-155731
    Antiviral agent 35 2760972-52-7 98%
    Antiviral agent 35 (compound 4d) is an orally active and potent influenza virus inhibitor, acting function in the early stage of virus replication. Antiviral agent 35 inhibits ROS accumulation, autophagy and apoptosis induced by influenza virus, and also inhibits inflammatory response mediated by RIG-1 pathway in mouse model with pulmonary infection. Antiviral agent 35 shows little cytotoxicity with CC50 >800 μM in MDCK cells, and anti-H1N1 (A/Weiss/43) activity with EC50 of 2.28 μM.
    Antiviral agent 35
  • HY-155734
    SARS-CoV-2-IN-55 98%
    SARS-CoV-2-IN-55(compound 65) is a low cytotoxicity inhibtor of SARS-CoV-2 with an IC50 value of 0.3 μM, by the direct interaction with VSV-S pseudoparticles.
    SARS-CoV-2-IN-55
  • HY-155746
    JAK2-IN-9 2568842-26-0 98%
    JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC50: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs).
    JAK2-IN-9
  • HY-155761
    Antifungal agent 71 98%
    Antifungal agent 71 (compound 6r) is a trifluoromethyl pyrimidine derivative with antifungal activity. Antifungal agent 71 exhibits good in vitro antifungal activity against F. oxysporum, with the EC50 value of 3.61 μg/mL.
    Antifungal agent 71
  • HY-155769
    Antimicrobial agent-24 98%
    Antimicrobial agent-24 (compound E8) is a hydrazide compound with excellent and broad-spectrum fungicidal activities. Antimicrobial agent-24 affects the normal function of the plasma membrane, further generating changes in the morphology and subcellular structure of mycelia.
    Antimicrobial agent-24
  • HY-155795
    Antiviral agent 37 357163-03-2 98%
    Antiviral agent 37 (Page 57) is an effective pUL97 inhibitor. Antiviral agent 37 can be used for the study of human cytomegalovirus (HCMV).
    Antiviral agent 37
  • HY-155801
    CRX 527 216014-14-1 98%
    CRX 527 is a TLR4 agonist. CRX 527 activates the MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, and regulates antigen processing and presentation by dendritic cells. CRX 527 stimulates innate immune responses and enhances vaccine efficacy. CRX 527 maintains the structural integrity of hematopoietic tissues, spleen and intestine, alleviates radiation-induced damage, preserves intestinal homeostasis, and inhibits apoptosis, inflammatory responses, oxidative stress and DNA damage. CRX 527 can be used in the research of acute radiation syndrome, melanoma, HPV-related tumors and intracerebral hemorrhage.
    CRX 527
  • HY-155831
    HCV-IN-43 1850311-28-2 98%
    HCV-IN-43 (compound 2) is an HCV NS5B protein inhibitor that can effectively inhibit the replication of HCV virus. HCV-IN-43 can be used for the study of HCV infection.
    HCV-IN-43
  • HY-155832
    HCV-IN-44 1850311-55-5 98%
    HCV-IN-44 (compound 28) is an HCV NS5B protein inhibitor that can effectively inhibit the replication of HCV virus. HCV-IN-44 can be used for the study of HCV infection.
    HCV-IN-44
  • HY-155833
    PI3Kδ-IN-13 1686137-02-9 98%
    PI3Kδ-IN-13 (compound 89) is a PI3Kδ inhibitor (IC50=2.6 nM). PI3Kδ-IN-13 can be used in the research of cell proliferation diseases such as cancer, infection, inflammation and autoimmune diseases.
    PI3Kδ-IN-13
  • HY-155834
    DprE1-IN-8 2679830-77-2 98%
    DprE1-IN-8 is a potent DprE1 inhibitor with an IC50 value of <0.75 μM. DprE1-IN-8 is against Mtb H37Rv with an IC50 of 6 nM and can be used for tuberculosis research.
    DprE1-IN-8
  • HY-155843
    CDK9-IN-25 98%
    CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM).
    CDK9-IN-25
  • HY-155845
    Antileishmanial agent-21 98%
    Antileishmanial agent-21 (compound 4e) is an antileishmanial agent that targets the Leishmania pteridine reductase 1 (Lm-PTR1). Antileishmanial agent-21 has an anti-folate mechanism, and folic acid and leucovorin can reverse the anti-leishmanial activity of Antileishmanial agent-21. Antileishmanial agent-21 inhibits the Chloroquine (HY-17589A)-resistant strain of Plasmodium falciparum (RKL9) with an IC50 of 0.0198-0.096 μM.
    Antileishmanial agent-21
  • HY-155846
    Antileishmanial agent-22 98%
    Antileishmanial agent-22 (compound 15b) is a parasite inhibitor and an antibacterial agent, with antileishmanial, antimalarial, and anti-tubercular activities. Antileishmanial agent-22 inhibits leishmanial (IC50=0.408 μM) based on antifolate mechanism. And, Antileishmanial agent-22 inhibits Folic acid and Folinic acid at 100 μM with inhibitory rates of 88% and 94%, respectively. Antileishmanial agent-22 inhibits P. berghei in vivo and in vitro, with 96.67% suppression under 48.4 μM/kg/day and 0.038 μM (IC50), respectively. Moreover, Antileishmanial agent-22 inhibits M. tuberculosis with MIC of 28.44 μM.
    Antileishmanial agent-22
  • HY-155968
    HBV-IN-40 98%
    HBV-IN-40 (Compound 11826096) is a HBV inhibitor (IC50: 0.7 μM). HBV-IN-40 is an antiviral agent.
    HBV-IN-40
  • HY-155970
    Urease-IN-7 1129406-54-7 98%
    Urease-IN-7 (Compound 5k) is a competitive Urease inhibitor (IC50: 3.33 μM, Ki: 3.62 μM). Urease-IN-7 can be used for research of peptic and gastric ulcers.
    Urease-IN-7
  • HY-155973
    Urease-IN-8 517906-16-0 98%
    Urease-IN-8 (Compound 5e) is a competitive Urease inhibitor (IC50: 3.51 μM, Ki: 3.11 μM). Urease-IN-8 can be used for research of peptic and gastric ulcers.
    Urease-IN-8
Cat. No. Product Name / Synonyms Application Reactivity